EU JCA Is Now Operational: What the First Assessments Reveal
About Evidence, RWE and Market Access
The European Union’s Joint Clinical Assessment framework has moved decisively from policy into practice.
Since the EU Health Technology Assessment Regulation became applicable in January 2025, pharmaceutical and biotechnology companies have been preparing for new timelines, evidence requirements and ways of working. In 2026, that preparation entered a more consequential phase: the first Joint Clinical Assessment (JCA) reports are now public, giving industry its first opportunity to see how the system operates in real cases.
The latest development came on 7 September 2026, when the European Commission published the JCA report for onasemnogene abeparvovec, marketed as Itvisma, an advanced therapy medicinal product for spinal muscular atrophy. The assessment was conducted by competent authorities in Ireland and France, endorsed by the Member State Coordination Group on HTA on 16 July 2026 and published following the product’s European marketing authorisation.
This follows earlier 2026 assessments involving Ojemda (tovorafenib), Imdylltra (tarlatamab) and Zepzelca (lurbinectedin). Taken together, these reports mark an important transition. EU JCA is no longer a theoretical compliance exercise. It is becoming a visible, evidence-intensive process with direct implications for clinical development, HEOR, real-world evidence and national market-access planning.
For pharmaceutical companies, the central question is no longer whether JCA will change evidence strategy. It is how early that change must begin.
One assessment does not mean one access decision
JCA creates a shared European assessment of a health technology’s relative clinical effectiveness and safety. It is intended to reduce duplication and provide Member States with a common scientific foundation for their national processes.
However, JCA does not produce a single European pricing or reimbursement decision.
National authorities will continue to evaluate matters such as cost-effectiveness, budget impact, local treatment pathways, affordability, implementation requirements and the place of a therapy within their healthcare system. They may also apply different economic methods, negotiate different prices or impose different access conditions.
For manufacturers, this creates a dual responsibility:
Develop a clinically credible evidence package that can withstand EU-level assessment.
Preserve sufficient flexibility to address national pricing and reimbursement requirements after the JCA is published.
The JCA dossier therefore cannot be developed as an isolated submission. It must sit within a broader European access strategy connecting clinical development, regulatory planning, HEOR, RWE and country-level execution.
PICO strategy is becoming a development decision
One of the most important changes introduced by JCA is the central role of the assessment scope, expressed through Population, Intervention, Comparator and Outcomes, PICO.
The relevant populations, comparators and outcomes may vary across Member States because clinical practice and standards of care are not identical across Europe. The resulting assessment scope may therefore contain several research questions that a manufacturer must address within a demanding submission timetable.
This makes PICO forecasting far more than a dossier-writing activity.
If a relevant comparator was not adequately considered when the pivotal clinical programme was designed, the evidence gap may be difficult to close later. If an important subgroup was not prospectively defined, or an outcome valued by HTA bodies was not collected, additional analysis may provide only a partial solution.
Pharma and biopharma companies should begin scenario-testing likely PICOs before pivotal-trial decisions are locked. This should include:
Mapping current and emerging comparators in priority Member States.
Identifying differences in treatment pathways and clinical practice.
Testing whether planned endpoints will support both regulatory and HTA questions.
Anticipating relevant subgroups and effect modifiers.
Assessing the feasibility of direct and indirect comparisons.
Identifying where external data or post-launch evidence may be needed.
The strategic implication is clear: market-access input must move further upstream in development.
Comparative evidence will receive greater scrutiny
The first wave of assessments reinforces the importance of comparative evidence. This is particularly challenging in oncology, rare diseases and advanced therapies, where randomised head-to-head trials may be difficult, unethical or unavailable.
In these circumstances, manufacturers may need to rely on single-arm trials, external control arms, indirect treatment comparisons or historical data. These approaches can be valuable, but they also introduce uncertainty around population comparability, confounding, endpoint definitions, treatment switching and data completeness.
The first published JCA, concerning tovorafenib, illustrates the practical consequences. The summary report records several PICO questions for which results were not included because relevant comparator data were unavailable in the target population. For another PICO, submitted results were not included because the available information was considered insufficient for assessing the comparator study.
This should not be interpreted as a conclusion about every future JCA. Product context matters, and rare paediatric diseases present distinctive evidence challenges. Nevertheless, it demonstrates that every analytical link—from data source selection to comparator justification and methodological documentation, must be defensible.
The question is not simply whether an analysis can be produced. It is whether assessors can determine that it is sufficiently transparent, relevant and reliable for the PICO it is intended to address.
Where real-world evidence can add value
Real-world evidence can play an increasingly important role in preparing for JCA and supporting the decisions that follow it.
Potential applications include:
Describing disease epidemiology and the eligible patient population.
Characterising current treatment pathways and standards of care.
Supporting external or synthetic control cohorts where appropriate.
Examining outcomes in underrepresented patient groups.
Assessing long-term effectiveness, safety and treatment durability.
Informing national budget-impact and implementation models.
Addressing evidence uncertainty through post-launch studies or managed-entry arrangements.
Europe’s RWE infrastructure is also expanding. EMA reports that DARWIN EU can access data from approximately 250 million patients through 40 data partners across 18 European countries. By its latest reporting period, 108 research topics had been assessed and 88 studies were completed or ongoing.
Scale alone, however, does not make evidence decision-grade.
RWE studies must begin with a clearly defined decision question. Data provenance, patient selection, variable definitions, missingness, bias, confounding and analytical choices must be documented. The dataset must be fit for the intended use, and the study design must reflect the relevant PICO rather than merely the data that happen to be available.
RWE should therefore be treated as part of an integrated evidence plan, not as a late attempt to repair weaknesses in the pivotal programme.
Advanced therapies intensify the evidence challenge
The publication of the Itvisma assessment is especially relevant because advanced therapies often combine potentially transformative clinical value with significant uncertainty.
Small eligible populations, limited comparator evidence, rapidly changing care pathways and the need to understand long-term durability can make conventional evidence generation difficult. At the same time, national payers may need to make substantial funding decisions while important questions remain unresolved.
This places greater importance on lifecycle evidence planning. Manufacturers should consider, early in development, how clinical-trial data, disease registries, natural-history studies, post-authorisation follow-up and national data sources can work together.
The objective is not to eliminate all uncertainty before launch, often an unrealistic expectation, but to make uncertainty explicit, quantify it where possible and establish a credible plan for reducing it over time.
Cross-functional governance is now essential
The compressed JCA process leaves little room for teams to work sequentially. Clinical development cannot complete its programme and simply hand the evidence to regulatory affairs, which then passes it to market access.
A more effective model brings together:
Clinical development
Regulatory affairs
Global and regional market access
HEOR and evidence synthesis
RWE and epidemiology
Biostatistics
Medical affairs
Country access teams
These functions need shared assumptions about the target population, comparators, endpoints, evidence gaps and submission responsibilities. They also need governance that can resolve disagreements early, before they become fixed in trial design or impossible to address within the JCA timeline.
Six actions pharmaceutical companies should take now
1. Run early PICO simulations
Do not wait for the formal assessment scope. Model credible PICO scenarios using clinical practice and HTA expectations across priority markets.
2. Connect JCA preparation to pivotal-trial design
Review whether planned comparators, endpoints, subgroups and follow-up periods can support likely European assessment questions.
3. Build an evidence-gap register
Record which questions can be answered directly, which require indirect evidence and which may remain uncertain at launch. Assign an owner and mitigation plan to each gap.
4. Pre-plan indirect comparisons
Assess evidence-network feasibility, population overlap and data availability early. Document analytical assumptions and prepare sensitivity analyses before timelines become compressed.
5. Design RWE for a defined decision
Link each RWE activity to a specific regulatory, JCA or national access question. Evaluate data fitness before commissioning the analysis.
6. Prepare for the national phase in parallel
JCA is a shared clinical assessment, not the end of market access. Country teams should prepare economic evidence, budget impact, local treatment pathways and payer engagement while the European process is underway.
From procedural readiness to evidence readiness
The first EU JCA reports should be treated as signals, not rigid templates. Each technology, indication and evidence base will present different challenges. It would be risky to assume that the experience of a rare paediatric oncology product or an advanced therapy will predict every future assessment.
Nevertheless, the direction is unmistakable.
Successful JCA preparation will depend less on completing a checklist shortly before submission and more on making better evidence decisions years earlier. Companies that connect clinical development, regulatory strategy, RWE and national market-access planning will be better positioned to respond to multiple PICOs, defend comparative analyses and explain residual uncertainty.
EU JCA has moved from regulation to reality. The competitive advantage will belong to organisations that move from procedural readiness to genuine evidence readiness.
Continue the discussion at the European RWE & Market Access Summit 2026
The practical implications of EU HTA, JCA, PICO strategy, payer expectations and real-world evidence will be explored at the European RWE & Market Access Summit 2026: JCA & PICO Strategy Edition.
Dates: 21–22 October 2026
Location: Inntel Hotels Amsterdam Landmark, Amsterdam, the Netherlands
Join senior professionals from pharmaceutical and biotechnology companies, HTA bodies, payer organisations, consultancies, data partners and evidence-solution providers to examine how Europe’s new assessment environment is changing evidence generation and access strategy.